EP4709409A2 - Cible métabolique pour la thérapie d'une inflammation vasculaire chronique - Google Patents

Cible métabolique pour la thérapie d'une inflammation vasculaire chronique

Info

Publication number
EP4709409A2
EP4709409A2 EP24804307.7A EP24804307A EP4709409A2 EP 4709409 A2 EP4709409 A2 EP 4709409A2 EP 24804307 A EP24804307 A EP 24804307A EP 4709409 A2 EP4709409 A2 EP 4709409A2
Authority
EP
European Patent Office
Prior art keywords
acss2
expression
sirna
endmt
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24804307.7A
Other languages
German (de)
English (en)
Inventor
Michael Simons
Pei Yu Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP4709409A2 publication Critical patent/EP4709409A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention comprend des compositions et des méthodes utiles pour le traitement d'une inflammation vasculaire chronique par l'inhibition de ACSS2.
EP24804307.7A 2023-05-11 2024-05-10 Cible métabolique pour la thérapie d'une inflammation vasculaire chronique Pending EP4709409A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363501556P 2023-05-11 2023-05-11
PCT/US2024/028722 WO2024233860A2 (fr) 2023-05-11 2024-05-10 Cible métabolique pour la thérapie d'une inflammation vasculaire chronique

Publications (1)

Publication Number Publication Date
EP4709409A2 true EP4709409A2 (fr) 2026-03-18

Family

ID=93431119

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24804307.7A Pending EP4709409A2 (fr) 2023-05-11 2024-05-10 Cible métabolique pour la thérapie d'une inflammation vasculaire chronique

Country Status (2)

Country Link
EP (1) EP4709409A2 (fr)
WO (1) WO2024233860A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3432913A4 (fr) * 2016-03-21 2020-03-04 Yale University Méthodes et compositions pour le traitement de l'athérosclérose
EP3687628A4 (fr) * 2017-09-26 2021-09-22 The Trustees of The University of Pennsylvania Compositions et méthodes pour inhiber acss2

Also Published As

Publication number Publication date
WO2024233860A2 (fr) 2024-11-14
WO2024233860A3 (fr) 2025-05-01

Similar Documents

Publication Publication Date Title
Rong et al. Hypoxic pretreatment of small extracellular vesicles mediates cartilage repair in osteoarthritis by delivering miR-216a-5p
JP7724504B2 (ja) 骨格筋ジストロフィーを治療する方法及び組成物
Schneider et al. S100A4: a common mediator of epithelial–mesenchymal transition, fibrosis and regeneration in diseases?
KR101627917B1 (ko) Cpne7 단백질을 포함하는 비치계 중간엽 줄기세포의 상아모세포로의 분화방법, 조성물 및 이를 이용한 치수조직 재생 및 상아질 지각과민증 치료용 약학적 조성물
Sandiford et al. Dual oxidase maturation factor 1 (DUOXA1) overexpression increases reactive oxygen species production and inhibits murine muscle satellite cell differentiation
CN1671742A (zh) Hmgb1在治疗组织损伤和/或促进组织修复中的用途
Zeng et al. Histone deacetylase 3 unconventional splicing mediates endothelial-to-mesenchymal transition through transforming growth factor β2
Zhao et al. The effect of overexpression of PGC-1α on the mtDNA4834 common deletion in a rat cochlear marginal cell senescence model
Ando et al. Tumor-specific interendothelial adhesion mediated by FLRT2 facilitates cancer aggressiveness
US20110065645A1 (en) Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance
Magadum et al. Phosphoserine aminotransferase 1 promotes serine synthesis pathway and cardiac repair after myocardial infarction
JP2020509768A (ja) エネルギー代謝を調節するポリペプチド及びその使用
WO2024233860A2 (fr) Cible métabolique pour la thérapie d'une inflammation vasculaire chronique
JP5553547B2 (ja) トロポニン含有医薬組成物
WO2013006841A1 (fr) Stimulation de la croissance collatérale artérielle et de la lymphogénèse
CN118460702A (zh) cGAS-STING信号通路在早产儿视网膜病变中的应用
EP1556410B1 (fr) Fragments peptidiques du facteur harp inhibant l'angiogenese
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
KR101662062B1 (ko) 코플린-1을 이용한 갈색 지방세포 분화 조절 방법
WO2006129867A2 (fr) Expression accrue de l'arn de lactoferrine par la lacritine
US20250215403A1 (en) Compositions and Methods for Cardiac Tissue Regeneration
JP2004123679A (ja) 好酸球カチオン性タンパク質を含有する組成物
JP2018508461A (ja) コラーゲンｖ由来のフラグメントの抗血管新生特性
Zhang et al. SIRT7 promotes dental pulp stem cells replicative senescence through desuccinylation of ROCK1
US12209111B2 (en) Targeting P18 for mTOR-related disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR